Menopur Mixed Protocol (COMBINE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01417195
First received: July 28, 2011
Last updated: May 6, 2014
Last verified: May 2014
  Purpose

The objective of this study was to compare the fertilization rate between the combination of Menopur and Bravelle mixed in the same syringe and Menopur alone, both administered subcutaneously (SC), in subjects undergoing Assisted Reproductive Technology (ART). Additionally the study assessed subjects' ability to mix and store the combination of Menopur and Bravelle and to assess safety of the Menopur and Bravelle combination.


Condition Intervention Phase
Infertility
Drug: Bravelle
Drug: Menopur
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Combination of Menopur® and Bravelle® With Menopur® Alone in Subjects Undergoing Assisted Reproductive Technology (ART)

Resource links provided by NLM:


Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Fertilization Rate [ Time Frame: approximately day 13 (16-20 hours post insemination by in vitro fertilization (IVF) insemination or intracytoplasmic sperm injection (ICSI)) ] [ Designated as safety issue: No ]
    The fertilization rate was defined for each participant and calculated as the number of 2 pronuclei (fertilized) (2PN) oocytes divided by the total number of oocytes retrieved multiplied by 100.


Secondary Outcome Measures:
  • Summary of the Subject Comprehension Questionnaire (SCQ) on Day 1 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    Subject comprehension questionnaires were completed on Day 1 only by participants assigned to the Menopur and Bravelle treatment arm. On Day 1, the participant read the Mixing Instructions Guide on how to mix and administer the medications at home. The participant was given enough time to read and understand the instructions and ask any questions. The participant then completed the SCQ which consists of 7 questions with YES/NO answers, to self-gauge their understanding of drug administration procedures. Reported data represent the number of participants who answered the question YES. Gonadotropins are referred to as investigational medicinal product (IMP).

  • Summary of the Subject Comprehension Questionnaire (SCQ) on Day 6 [ Time Frame: Day 6 ] [ Designated as safety issue: No ]
    Subject comprehension questionnaires were repeated on Day 6 after 5 days of combination therapy by participants assigned to the Menopur and Bravelle treatment arm. The SCQ consists of 7 questions with YES/NO answers to self-gauge participants' understanding of drug administration procedures. Reported data represent the number of participants who answered the question YES. Gonadotropins are referred to as investigational medicinal product (IMP).

  • Summary of Assessor Questionnaire on Day 1 [ Time Frame: Day 1 ] [ Designated as safety issue: No ]

    Participants assigned to the Menopur and Bravelle treatment arm read the Mixing Instructions Guide on how to mix and administer the medications at home. Participants were given enough time to read and understand the instructions and ask any questions. After completing the SCQ, participants prepared and self-administered her assigned first daily dose in the presence of the study coordinator or designee assessor. The assessor then completed a 7 question questionnaire with YES or NO answers to document their assessment of participant understanding of drug administration procedures. Reported data represent the number of participants for whom the assessor answered the question YES.

    Gonadotropins are referred to as investigational medicinal product (IMP).


  • Summary of Assessor Questionnaire on Day 6 [ Time Frame: Day 6 ] [ Designated as safety issue: No ]

    Participants assigned to the Menopur and Bravelle treatment arm prepared and self-administered her daily dose on Day 6 in the presence of the study coordinator or designee assessor. The assessor then completed a 7 question questionnaire with YES or NO answers to document their assessment of participant understanding of drug administration procedures. Reported data represent the number of participants for whom the assessor answered the question YES.

    Gonadotropins are referred to as investigational medicinal product (IMP).


  • Participants With Treatment Emergent Adverse Events (TEAEs), Including Ovarian Hyperstimulation Syndrome (OHSS) [ Time Frame: Day 1 up to Day 20 ] [ Designated as safety issue: Yes ]
    A treatment-emergent AE was any AE occurring after start of investigational medicinal product (IMP) and within the time of residual drug effect, or a pretreatment AE or pre-existing medical condition that worsened in intensity after start of IMP and within the time of residual drug effect. The time of residual drug effect was the estimated period of time after the last dose of the IMP, where the effect of the product was still considered to be present based on pharmacokinetic, pharmacodynamic, or other IMP characteristics.


Enrollment: 122
Study Start Date: July 2011
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Menopur and Bravelle combination
The initial daily dose consisted of 225 IU of gonadotropins, mixed in the same syringe and administered by subcutaneous (SC) injection for 5 days. The initial daily dose, based on the Investigator's judgment, consisted of either 150 IU of Menopur and 75 IU of Bravelle or 150 IU of Bravelle and 75 IU of Menopur. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and was always to include at least 75 IU of Menopur and 75 IU of Bravelle. Treatment could not continue beyond day 20.
Drug: Bravelle
Other Names:
  • Bravelle®
  • Urofollitropin
  • purified form of follicle-stimulating hormone (FSH)
Drug: Menopur
Other Names:
  • Menopur®
  • Menotropin
  • HP-hMG
  • highly purified menotrophin
Active Comparator: Menopur alone
The initial daily dose consisted of 225 IU of Menopur administered by subcutaneous (SC) injection for 5 days. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and treatment could not continue beyond day 20.
Drug: Menopur
Other Names:
  • Menopur®
  • Menotropin
  • HP-hMG
  • highly purified menotrophin

  Eligibility

Ages Eligible for Study:   18 Years to 42 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • Infertile pre-menopausal female subjects
  • Documented history of infertility (eg., unable to conceive for at least 1 year, or 6 months for women ≥36 years of age, or women with bilateral tubal occlusion or absence, or subjects who require donor sperm).
  • Subject's male partner with semen analysis that was at least adequate for intracytoplasmic sperm injection (ICSI) within 6 months prior to the subjects beginning down-regulation with gonadotropin-releasing hormone (GnRH)-agonist. Partners with severe male factor requiring invasive or surgical sperm retrieval or donor sperm could have been used.
  • Anti-mullerian hormone (AMH) > 1 ng/mL and < 3 ng/mL at screening.
  • Eligible for in-vitro fertilisation (IVF) or ICSI treatment.

Main Exclusion Criteria:

  • Oocyte donor or embryo recipient; gestational or surrogate carrier
  • Previous IVF or assisted reproductive technology (ART) failure due to a poor response to gonadotropins. Poor response was defined as development of ≤ 2 mature follicles or history of 2 previous failed cycle cancellations prior to oocyte retrieval due to poor response.
  • Inadequate number of oocytes, defined as fewer than 5 oocytes retrieved in previous ART attempts.
  • Subject's male partners with obvious leukospermia (>2 million white blood cells [WBC]/mL) or signs of infection in semen sample within 2 months of the start of subject's pituitary down-regulation. If either of these conditions existed, the male was to be treated with antibiotics and retested prior to subject's pituitary down-regulation.
  • Undergoing blastomere biopsy and other experimental ART procedures.
  • Body mass index (BMI) of ≤18 and ≥32 kg/m^2
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01417195

Locations
United States, Colorado
Colorado Center for Reproductive Medicine
Lone Tree, Colorado, United States
United States, Florida
Women's Medical Research Group
Clearwater, Florida, United States
United States, Georgia
Reproductive Biology Associates
Atlanta, Georgia, United States
United States, Illinois
Fertility Center of Illinois
Chicago, Illinois, United States
The Advanced IVF Institute
Naperville, Illinois, United States
United States, Maryland
Shady Grove Fertility
Rockville, Maryland, United States
United States, Texas
The Center for Assisted Reproduction
Bedford, Texas, United States
Houston Fertility Institute
Houston, Texas, United States
Center of Reproductive Medicine
Webster, Texas, United States
United States, Washington
Seattle Reproductive Medicine
Seattle, Washington, United States
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

No publications provided

Responsible Party: Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01417195     History of Changes
Other Study ID Numbers: FE999906 CS12
Study First Received: July 28, 2011
Results First Received: March 20, 2014
Last Updated: May 6, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Ferring Pharmaceuticals:
Assisted Reproductive Technology

Additional relevant MeSH terms:
Infertility
Genital Diseases, Female
Genital Diseases, Male
Follicle Stimulating Hormone
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 20, 2014